New Year's Resolutions For The U.S. Patent System

02 January 2018 PharmaPatents Blog
Authors: Courtenay C. Brinckerhoff

It’s that time of year when we make resolutions to improve our health, our relationships, our careers, or other areas of our lives. I’m not starting a new diet today (although if I were, the invention described in this patent application could be helpful), but I have been thinking about New Year’s resolutions for the U.S. patent system.

Make Diagnostic Methods Patentable Again

It’s been nearly six years since the Supreme Court called the patent eligibility of diagnostic methods into question in Mayo v. Prometheus, and two and a half years since the Federal Circuit twisted the knife with its decision in Ariosa v. Sequenom. The USPTO issued guidelines to help stakeholders navigate the newly treacherous § 101 terrain, but when even the Patent Trial and Appeal Board doesn’t let applicants follow those narrow paths, it’s no surprise that individual examiners find roadblocks where none used to be. Several organizations are working on proposed legislative “fixes,”but any changes to the statute are a long way off. Until then, we struggle to devise intellectual property strategies when it remains possible to patent diagnostic inventions in other major IP markets, including Europe and Japan, but not always Canada or China.

Reduce The Duty of Disclosure Burden

It wouldn’t take an act of Congress to reduce the Duty of Disclosure burden. The USPTO could implement revised examination practices and document review procedures that would alleviate the costly and wasteful processes required by the current IDS rules and related MPEP guidance. For example, applicants should be able to cross-cite references from copending applications without having to actually upload copies of the references into each electronic file wrapper. And there’s no reason to treat published PCT applications differently from published U.S. applications when they are readily available from the WIPO Patentscope website. And why require applicants to submit references cited in corresponding foreign applications that are readily available—with machine translations—on the USPTO’s own Global Dossier website? Or, how about updating the Duty of Disclosure in view of Therasense?

Remind The Public That Patents Promote Innovation, Investment and Job Creation

While it’s fun to make fun of ridiculous patents, it’s important to remind the public that most patents protect key technologies that drive business growth. Especially in life sciences fields, if patent protection is not available companies may not invest in bringing new innovations to market–and won’t hire the scientists, engineers, and sales forces those new products would require. The public should know that a strong patent system is key to a strong U.S. economy–even if a few silly patents get granted.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Insights

PATH Summit 2019
18-20 December 2019
Arlington, VA
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.